Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 5

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi Cheng, William H. Prusoff · Biochemical Pharmacology · 1973 · 12.9K citations

Life Sciences, Biochemistry, Chemical Kinetics +14

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy et al. · Advanced Drug Delivery Reviews · 1997 · 11.2K citations

Pharmacy, Pharmacokinetics, Pharmacology +16

A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635

Elaine A. Forster, Ian A. Cliffe, David J. Bill et al. · European Journal of Pharmacology · 1995 · 611 citations

Medicine, Pharmacology, General Pharmacology +8

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

Benny Bang‐Andersen, Thomas Ruhland, Morten Jørgensen et al. · Journal of Medicinal Chemistry · 2011 · 602 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.

Pau Celada, M. Victoria Puig, Mercè Amargós‐Bosch et al. · PubMed · 2004 · 493 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17